News Center
Share the latest news with you
Impact Therapeutics Announces Completion of Series D1 Financing
2022-04-15
IMPACT Therapeutics announced the successful completion of its Series D1 financing on SHANGHAI, March 14, 2022. Institutional investors that participated in this round include new investors Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management led by Sam Isaly, along with existing shareholders LAV (Lilly Asia Ventures), China Summit, and Yuexiu. Proceeds will be used to accelerate the development of its synthetic lethality programs, many of which are showing best-in-class potential.
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. In 2021, IMPACT achieved breakthroughs on multiple targets including PARP, Wee1, and ATR, becoming one of the biotech companies with the widest DDR pipelines in the world and is expanding to other novel synthetic lethality targets to broaden its pipelines. Today, the company already has three synthetic lethality compounds in the clinical stage.
Dr. Jun Bao, President and CEO of IMPACT Therapeutics said: "We thank these excellent investment institutions for their support and trust in IMPACT. The successful closing gave us more confidence to implement our global development strategy and advance various clinical trials at full speed. We look forward to working with clinical investigators and other partners to bring more efficacious therapies to patients around the world."
Last
IMPACT Announces Presentation of the Clinical Data for Senaparib in Combination with Temozolomide and the Monotherapy of Wee1 Inhibitor at the ASCO 2022
Next
IMPACT Announces Acceptance of Two Abstracts of Senaparib for Presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 苏ICP备 10223379号 苏公网安备 32011202000351 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
